Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 2, 1997, Pages 710-720

  Smith, Craig P ^a   Bores, Gina M ^a   Petko, Wayne ^a   Li, Mary ^a   Selk, David E ^a   Rush, Douglas K ^a   Camacho, Fernando ^a   Winslow, James T ^a   Fishkin, Rod ^a   Cunningham, Dana M ^a   Brooks, Karen M ^a   Roehr, Joachim ^a   Hartman, Harold B ^a   Davis, Larry ^a   Vargas, Hugo M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(3 FLUORO 4 PYRIDINYL)AMINO] 3 METHYL 1H INDOL 5 YL METHYLCARBAMATE; ACETYLCHOLINESTERASE; AMINOACRIDINE; BRAIN ENZYME; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HOMOVANILLIC ACID; PHYSOSTIGMINE DERIVATIVE; SCOPOLAMINE; TACRINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; AVOIDANCE BEHAVIOR; CHOLINERGIC STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME ACTIVITY; HEART RATE; HYPOTHERMIA; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ACETYLCHOLINESTERASE; ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMINOPYRIDINES; ANIMALS; AVOIDANCE LEARNING; BRAIN; BUTYRYLCHOLINESTERASE; CARBAMATES; CHOLINESTERASE INHIBITORS; CORPUS STRIATUM; DOPAMINE; FEMALE; HUMANS; HYPOTHERMIA, INDUCED; KINETICS; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED STRAINS; OVARIECTOMY; PROSENCEPHALON; RATS; RATS, WISTAR; SCOPOLAMINE; SOCIAL BEHAVIOR; SPACE PERCEPTION; TIME FACTORS;

EID: 15644368835     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. ARAI, H., ICHIMIYA, Y., KOSAKA, K., MOROJI, T. AND IIZUKA, R.: Neurotransmitter changes in early- and late-onset alzheimer-type demetia. Prog. Neuropsychopharmacol. Biol. Psychiat. 16: 883-890, 1992.
2. BARTUS, R. T. AND JOHNSON, H. R.: Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol. Biochem. Behav. 5: 39-46, 1976.
3. BARTUS, R. T., DEAN, R. L., BEER, B. AND LIPPA, A. S.: The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-417, 1982.
4. BORES, G. M., HUGER, F. P., PETKO, W., MUTLIB, A. E., CAMACHO, F., RUSH, D. K., SELK, D. E., WOLF, V., KOSLEY, R. W., JR., DAVIS, L. AND VARGAS, H. M.: pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine. J. Pharmacol. Exp. Ther. 277: 728-738, 1996.
5. BOWEN, D. M., SPILLANE, J. A., CURZON, G., MEIER-RUGE, W., WHITE, P., IWAN-GOFF, P. AND DAVISON, A. N.: Accelerated aging or selective neuronal loss as an important cause of dementia. Lancet 1: 11, 1979.
6. BREZENOFF, H. E. AND GUILIANO, R.: Cardiovascular control by cholinergic mechanisms in the central nervous system. Annu. Rev. Pharmacol. Toxicol. 22: 341-81, 1982.
7. BRUFANI, M., CASTELLANO, C., MARTA, M., OLIVERIO, A., PAGELLA, P. G., PAVONE, F., POMPONI, M. AND RUGARLI, P. L.: A long-lasting cholinesterase inhibitor affecting neural and behavioral processes. Pharmacol. Biohcem. Behav. 26: 625-629, 1987.
8. 2Adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 124: 347-354, 1996.
9. CUMIN, R., BANDLE, E. F., GAMZU, E. AND HAEFELY, W. E.: Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology 78: 104-111, 1982.
10. COMMISSIONG, J. W.: Monoamine metabolites: Their relationship and lack of relationship to monoaminergic neuronal activity. Biochem. Pharmacol. 34: 1127-1131, 1985.
11. COYLE, J. T., PRICE, D. L. AND DELONG, M. R.: Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219: 1184-1190, 1983.
12. DAVIES, P. AND MALONEY A. J. F.: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403, 1976.
13. DAVIS, K. L., THAL, L. J., GAMZU, E. R., DAVIS, C. S., WOOLSON, R. F., GRACON, S. I.,FRACHMAN, D. A., SCHNEIDER, L., WHITEHOUSE, P. J., HOOVER, T. M., MORRIS, J. C., KAWAS, C. H., KNOPMAN, D. S., EARL, N. L., KUMAR, V., DOODY, R. S. AND THE TACRINE COLLABORATIVE STUDY GROUP: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N. Engl. J. Med. 327: 1253-1259, 1993.
14. DAVIS, L., KLEIN, J. T., OLSEN, G. E., NEMOTO, P., WETTLAUFER, D. G., CORNFELDT, M. L., HUGER, F. P., RUSH, D. K., SELK, D., SMITH, C. P., PETKO, W. W., BORES, G. M., BROUGHAM, L. R., WILKER, J. AND EFFLAND, R. C.: Synthesis and SAR of carbamate analogs of the 4-pyridinyl-1H-indol-1-amine HP 749: Potential agents for the treatment of Alzheimer's disease (Abstract), 203rd Am. Chem. Soc. Natl. Meeting (MEDI 103), San Francisco, CA, April 5-10, 1992.
15. DUNNETT, S. B.: Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Pyschopharmacology 87: 357-363, 1985.
16. ELLMAN, G. L., COURTNEY, K. D., ANDRES, V., JR. AND FEATHERSTONE, R. M.: A new and rapid colormetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7: 88-95, 1961.
17. FIELDING, S., LAL, H., DOBRIN, E. I. AND NIEMEGEERS, C. J. E.: Preclinical neuropsychopharmacology of neuroleptics. In Neuroleptics, Industrial Pharmacology, Vol 1, ed. by S. Fielding and H. Lal, Futura Publishing Co., Mount Kisco, NY, 1974.
18. FREEMAN, S. E. AND DAWSON, R. M.: Tacrine: a pharmacological review. Prog. Neurobiol. 36: 257-277, 1991.
19. GHEUSI G., BLUTHE R.-M., GOODAL G. AND DANTZER R.: Ethological study of the effects of tetrahydoaminoacridine (THA) on social recognition in rats. Psychopharmacology 114: 664-650, 1994.
20. GORDON, C. J.: Thermoregulation in laboratory mammals and humans exposed to anticholinesterase agents. Neurotoxicol. Teratol 16: 427-453, 1994.
21. IRWIN, S.: Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13: 222-257, 1968.
22. KEWITZ, H., WILCOCK, G. AND DAVIS, B.: Galanthamine in Alzheimer's disease. In Alzheimer's Disease: Therapeutic Strategies, ed. by E. Giacobini and R. Becker, pp. 140-144, Birkhauser, Boston, 1994.
23. KLEIN, J. T., DAVIS, L., OLSEN, G. E., WONG, G. S., HUGER, F. P., SMITH, C. P., PETKO, W. P., CORNFELDT, M., WILKER, J., BLITZER, R. D., LANDAU, E., HAROU-TUNIAN, V., MARTIN, L. L. A. EFLLAND, R. C.: Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's Disease. J. Med. Chem. 39: 570-581, 1996.
24. KNAPP, M. J., KNOPMAN, D. S., SOLOMON, P. R., PENDLEBURY, W. W., DAVIS, C. S., GRACON, S. I. AND THE TACRINE STUDY GROUP: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J.A.M.A. 271: 985-991, 1994.
25. KUKAN, M., BEZEK, S., POOL, W. F. AND WOOLF, T. F.: Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver: In vitro / in vivo comparisons. Xenobiotica 24: 1107-1111, 1994.
26. NIELSEN, J. A., MENA, E. E., WILLIAMS, J. H., NOCERINI, M. R. AND LISTON, D.; Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Psychopharmacologia 105: 134-136, 1991.
27. MADDEN, S., WOOLF, T. F., POOL, W. F. AND PARK, B. K.: An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine: In vitro studies with human liver microsomes. Br. J. Clin. Pharmacol, 36: 145P, 1993.
28. PERIO A., TERRANOVA, J. P., WORMS P., BLUTHE, R. M., DANTZER, R. AND BIZIERE K.: Specific modulation of social memory in rats by cholinomimetic and nontropic drugs, by benzodiazepine inverse agonists, but not by psychostimulants. Pyschopharmacology 97: 262-8, 1989.
29. POMARA, N., NOLAN, K. AND HALPERN, G.: Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with apolipoprotein E type 4 alleles, Neurochem. Res. 20: 1519-1520, 1995.
30. 4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's Disease. Proc. Natl. Acad. Sci. U.S.A. 92: 12260-12264, 1995.
31. RASKIND, M. A., CARTA, A. AND BRAVI, D.: Is early-onset Alzheimer's disease a distinct subgroup within the Alzheimer disease population? Alzheimer Dis. Assoc. Discord. 9(Suppl 1): S2-S6, 1995.
32. ROGERS, S. L. AND FRIEDHOFF, L. T.: Donepezil (E2020) produces long-term clinical improvement in Alzheimer's Disease. Fourth International Nice/ Springfield Symposium on Advances in Alzheimer Therapy, p. 56, Southern Illinois Univ, Springfield, IL, April 10-14, 1996.
33. SARTER, M., HAGAN, J. AND DUDCHENKO, P.: Behavioral screening for cognition enhancers: From indiscriminate to valid testing: Part I. Psychopharmacology 107: 144-159, 1992a.
34. SARTER, M., HAGAN, J. AND DUDCHENKO, P.: Behavioral screening for cognition enhancers: From indiscriminate to valid testing: Part II. Psychopharmacology 107: 461-473, 1992b.
35. SCHELLENBERG, G. D.: Genetic dissection of Alzheimer's disease, a heterogeneous disorder. Proc. Natl. Acad. Sci. U.S.A. 92: 8552-8559, 1995.
36. SIEGFRIED, K.: The efficacy of cholinergic drugs in patients with Alzheimer's disease - Focus on the aminoacridines. Hum. Psychopharmacol. 10: 89-96, 1995.
37. SMITH, C. P., BROUGHAM, L. R., HUGER, F. P., DAVIS, L., KLEIN, J. T. AND EFFLAND, R. C.: N-(n-propyl)-N-(3-fluoro-4-pyridinyl)-1H-3-methylindol-l-amine hydrochloride (HP 184): In vitro spontaneous release of acetylcholine and norepinephrine. Drug Dev. Res. 30: 203-212, 1993.
38. 3H]norepinephrine release from rat cortical slices by N-(n-propyl)-N-(4-pyridinyl)-1H-indol-1-amine. Drug Dev. Res. 32: 13-18, 1994.
39. STRITTMATTER, W. J. AND ROSES, A. D.: Apolipoprotein E and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 92: 4725-4727, 1995.
40. SUMMERS, W. K., MAJOVSKI, L. V., MARSH, G. M., TACHIKI, K. AND KLING, A.: Oral tetrahydroaminoacridine in long-term treatment of senile. N. Engl. J. Med. 315: 1241-1245, 1986.
41. THOMSEN, T., BICKEL, U., FISCHER, J. P. AND KEWITZ, H.: Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1; 46-51, 1990.
42. VARGAS, H. M. AND RINGDAHL, B.: Centrally active antimuscarinic analogs of oxotrernorine selectively block physostigmine-induced hypertension, but not peripheral muscarinic vasodepression. J. Pharmacol. Exp. Ther. 253: 165-170, 1990.
43. 1B adrenoceptor antagonist, in the unanesthetized rat: A pharmacological analysis in vivo and in vitro. J. Pharmacol. Exp. Ther. 266: 864-871, 1993.
44. VIDALUC, J. L., CALMEL, F., BIGG, D., CARILLA, E., STENGER, A., CHOPIN, P. AND BRILEY, M.: Novel [2-(4-piperidinyl)ethyl](thio)ureas: Synthesis and anticholinesterase activity. J. Med. Chem. 37: 8689-695, 1994.
45. WAITE, J. J. AND THAL, L. J.: The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis. Neurosci. Res. 21: 251-259, 1995.
46. WAGNER, J., VITALI, P., PALFREYMAN, M. G., ZRAIKA, M. AND HUOT, S.: Simultaneous dtermination of 3,4-dihyroxyphenylalanine, 5-hyrdroxytrytophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, serotonin and 5-hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high-performance liquidchromatography with electrochemical detection. J. Neurochem. 38: 1241-1254, 1982.
47. WATKINS, P. B., ZIMMERMAN, H. J., KNAPP, M. J., GRACON, S. I. AND LEWS, K. W.: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J.A.M.A. 271: 992-998, 1994.
48. WHITEHOUSE, P. J., PRICE, D. L., CLARK, A. W., COYLE, J. T. AND DELONG, M. R.: Alzheimer's disease; Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 10: 122-128, 1981.
49. WHITEHOUSE, P. J., PRICE, D. L., STRUBLE, R. G., CLARK, A. W., COYLE, J. T. AND DELONG, M. R.: Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 215: 1237-1239, 1982.
50. WINSLOW, J. T., HASTINGS, N., CARTER, C. S., HARBAUGH, C. R. AND INSEL, T. R.: A role for vasopressin in pair bonding in monogamous prairie voles. Nature 365: 546-549, 1993.
51. WINSLOW, J. T. AND CAMACHO, F.: Cholinergic modulation of a decrement in social investigation following repeated contacts between mice. Psychopharmacology 121: 164-172, 1995.
52. WORMS P., KAN J.-P., STEINBERG R., TERRANOVA J.-P., PERIO A. AND BIZIERE K.: Cholinomimetic activities of minaprine. Naunyn-Schmiedeberg Arch. Pharmacol. 340: 411-418, 1989.
53. 2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats. Brain Res. 495: 232-236, 1989.
54. YAMANISHI, Y., KOSASA, T. AND KANEKO, T.: E2030, a novel acetylcholineasterase inhibitor (1): Neurochemical studies on the central nervous system (Abstract). Neuroscience 18: 340, 1992.
55. ZHU, X. D., GIACOBINI, E. AND HORNSBERGER, J. M.: Effect of MDL 73,745 on acetylcholine and biogenic amine levels in rat cortex. Eur. J. Pharmacol 276: 93-99, 1995.